68 related articles for article (PubMed ID: 30556601)
21. EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.
Laurenzana A; Margheri F; Biagioni A; Chillà A; Pimpinelli N; Ruzzolini J; Peppicelli S; Andreucci E; Calorini L; Serratì S; Del Rosso M; Fibbi G
EBioMedicine; 2019 Jan; 39():194-206. PubMed ID: 30611716
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.
Mohapatra P; Prasad CP; Andersson T
Mol Oncol; 2019 Feb; 13(2):480-494. PubMed ID: 30582770
[TBL] [Abstract][Full Text] [Related]
23. Pro-Apoptotic Activity of MCL-1 Inhibitor in Trametinib-Resistant Melanoma Cells Depends on Their Phenotypes and Is Modulated by Reversible Alterations Induced by Trametinib Withdrawal.
Hartman ML; Koziej P; Kluszczyńska K; Czyz M
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835493
[TBL] [Abstract][Full Text] [Related]
24. Trametinib-Resistant Melanoma Cells Displaying MITF
Koziej P; Kluszczynska K; Hartman ML; Czyz M
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175614
[TBL] [Abstract][Full Text] [Related]
25. Targeting senescence as an anticancer therapy.
Bousset L; Gil J
Mol Oncol; 2022 Nov; 16(21):3855-3880. PubMed ID: 36065138
[TBL] [Abstract][Full Text] [Related]
26. Structural and Biofunctional Insights into the Cyclo(Pro-Pro-Phe-Phe-) Scaffold from Experimental and In Silico Studies: Melanoma and Beyond.
Bojarska J; Breza M; Remko M; Czyz M; Gajos-Michniewicz A; Zimecki M; Kaczmarek K; Madura ID; Wojciechowski JM; Wolf WM
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806175
[TBL] [Abstract][Full Text] [Related]
27. Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer.
Delahaye C; Figarol S; Pradines A; Favre G; Mazieres J; Calvayrac O
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681591
[TBL] [Abstract][Full Text] [Related]
28. Deciphering the Functional Role of RIPK4 in Melanoma.
Madej E; Ryszawy D; Brożyna AA; Czyz M; Czyz J; Wolnicka-Glubisz A
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768934
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological-Associated Regulatory Network of Deregulated circRNAs in Hepatocellular Carcinoma.
Han J; Thurnherr T; Chung AYF; Goh BKP; Chow PKH; Chan CY; Cheow PC; Lee SY; Lim TKH; Chong SS; Ooi LLPJ; Lee CG
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199580
[TBL] [Abstract][Full Text] [Related]
30. Senolytics for Cancer Therapy: Is All That Glitters Really Gold?
Carpenter VJ; Saleh T; Gewirtz DA
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33578753
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Benign and Malignant Pilomatricomas Using Whole-exome Sequencing.
Yeo MK; Bae GE
Cancer Genomics Proteomics; 2020; 17(6):795-802. PubMed ID: 33099480
[TBL] [Abstract][Full Text] [Related]
32. Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells.
Osrodek M; Rozanski M; Czyz M
Cancer Manag Res; 2020; 12():7231-7250. PubMed ID: 32982400
[TBL] [Abstract][Full Text] [Related]
33. Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications.
Vanni I; Tanda ET; Dalmasso B; Pastorino L; Andreotti V; Bruno W; Boutros A; Spagnolo F; Ghiorzo P
Front Mol Biosci; 2020; 7():172. PubMed ID: 32850962
[TBL] [Abstract][Full Text] [Related]
34. Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.
Walcher L; Kistenmacher AK; Suo H; Kitte R; Dluczek S; Strauß A; Blaudszun AR; Yevsa T; Fricke S; Kossatz-Boehlert U
Front Immunol; 2020; 11():1280. PubMed ID: 32849491
[TBL] [Abstract][Full Text] [Related]
35. 17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines.
Hartman ML; Rogut M; Mielczarek-Lewandowska A; Wozniak M; Czyz M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32466509
[TBL] [Abstract][Full Text] [Related]
36. Non-Apoptotic Cell Death Signaling Pathways in Melanoma.
Hartman ML
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340261
[TBL] [Abstract][Full Text] [Related]
37. Therapy-Induced Senescence: An "Old" Friend Becomes the Enemy.
Saleh T; Bloukh S; Carpenter VJ; Alwohoush E; Bakeer J; Darwish S; Azab B; Gewirtz DA
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235364
[TBL] [Abstract][Full Text] [Related]
38. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of HSP90 in melanoma.
Mielczarek-Lewandowska A; Hartman ML; Czyz M
Apoptosis; 2020 Feb; 25(1-2):12-28. PubMed ID: 31659567
[TBL] [Abstract][Full Text] [Related]
40. TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF
Hartman ML; Czyz M
Arch Dermatol Res; 2020 Jul; 312(5):385-392. PubMed ID: 31624899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
